« Previous Next » The Journal of Heart and Lung Transplantation
Volume 29, Issue 6 , Pages 616-624 , June 2010

Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy

Mark S. Slaughter, MD
- Division of Thoracic and Cardiovascular Surgery, University of Louisville, Louisville, Kentucky
- Reprint requests: Mark S. Slaughter, MD, University of Louisville, 201 Abraham Flexner Way, Suite 1200, Louisville, KY 40202. Telephone: 502-561-2180. Fax: 502-561-2190
Yoshifumi Naka, MD
- Department of Surgery and the Cardiac Transplantation and Mechanical Circulatory Support Programs, Columbia University, New York, New York
Ranjit John, MD
- Division of Cardiothoracic Surgery, University of Minnesota, Minneapolis, Minnesota
Andrew Boyle, MD
- Division of Cardiology, University of Minnesota, Minneapolis, Minnesota
John V. Conte, MD
- Division of Surgery, Johns Hopkins University, Baltimore, Maryland
Stuart D. Russell, MD
- Division of Cardiology and the Heart Failure and Transplantation Program, Johns Hopkins University, Baltimore, Maryland
Keith D. Aaronson, MD
- Department of Internal Medicine and the Heart Failure Program, University of Michigan, Ann Arbor, Michigan
Kartik S. Sundareswaran, PhD
- Thoratec Corporation, Pleasanton, California
David J. Farrar, PhD
- Thoratec Corporation, Pleasanton, California
Francis D. Pagani, MD, PhD
- Section of Cardiac Surgery, University of Michigan, Ann Arbor, Michigan

Mean (± SD) partial thromboplastin time (PTT) values for the three study groups for the first 21 VAD post-operative days. Group A: therapeutic heparin; Group B: sub-therapeutic heparin; Group C: no he

Mean (± SD) partial thromboplastin time (PTT) values for the three study groups for the first 21 VAD post-operative days. Group A: therapeutic heparin; Group B: sub-therapeutic heparin; Group C: no heparin. POD, post-operative day.
- Full-Size Image
- Download to PowerPoint
Mean (± SD) international normalized ratio (INR) values for the three study groups for the first 21 VAD post-operative days. Group A: therapeutic heparin; Group B: sub-therapeutic heparin; Group C: no

Mean (± SD) international normalized ratio (INR) values for the three study groups for the first 21 VAD post-operative days. Group A: therapeutic heparin; Group B: sub-therapeutic heparin; Group C: no heparin. POD, post-operative day.
- Full-Size Image
- Download to PowerPoint
Percentage of patients with any bleeding or thrombotic adverse event during the first 3 to 30 days after the operation. Bleeding events = bleeding requiring surgery, bleeding requiring >2 units of pac

Percentage of patients with any bleeding or thrombotic adverse event during the first 3 to 30 days after the operation. Bleeding events = bleeding requiring surgery, bleeding requiring >2 units of packed red blood cells per 24 hours or hemorrhagic stroke; thrombotic events = ischemic stroke or pump thrombosis. Group A: therapeutic heparin; Group B: sub-therapeutic heparin; Group C: no heparin. The p-value indicates the difference between groups according to the chi-square test.
- Full-Size Image
- Download to PowerPoint